Christopher A. Eide

10.2k total citations · 2 hit papers
97 papers, 3.9k citations indexed

About

Christopher A. Eide is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Christopher A. Eide has authored 97 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Hematology, 59 papers in Genetics and 33 papers in Molecular Biology. Recurrent topics in Christopher A. Eide's work include Chronic Myeloid Leukemia Treatments (64 papers), Chronic Lymphocytic Leukemia Research (46 papers) and Acute Myeloid Leukemia Research (34 papers). Christopher A. Eide is often cited by papers focused on Chronic Myeloid Leukemia Treatments (64 papers), Chronic Lymphocytic Leukemia Research (46 papers) and Acute Myeloid Leukemia Research (34 papers). Christopher A. Eide collaborates with scholars based in United States, India and Brazil. Christopher A. Eide's co-authors include Brian Druker, Thomas O’Hare, Michael W. Deininger, Jeffrey Tyner, Theodore P. Braun, Anupriya Agarwal, Stephanie G. Willis, Shannon K. McWeeney, Marc Loriaux and Cristina E. Tognon and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Christopher A. Eide

88 papers receiving 3.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML

2013 356 citations Julia E. Maxson, Jason Gotlib et al. profile →
Response and Resistance to BCR-ABL1-Targeted Therapies

2020 308 citations Christopher A. Eide, Brian Druker et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Christopher A. Eide	2.3k	1.6k	1.6k	802	725	97	3.9k
Shu Tamura	2.5k 1.1×	1.0k 0.6×	1.6k 1.0×	713 0.9×	1.1k 1.6×	11	3.7k
Charles Chuah	3.5k 1.5×	1.1k 0.7×	2.7k 1.7×	860 1.1×	1.6k 2.2×	108	4.6k
Markus Warmuth	1.2k 0.5×	1.7k 1.1×	885 0.6×	930 1.2×	411 0.6×	48	3.1k
Yaping Shou	1.8k 0.8×	1.1k 0.7×	1.5k 0.9×	686 0.9×	826 1.1×	68	3.1k
Gerald M. Segal	2.5k 1.1×	953 0.6×	1.4k 0.9×	628 0.8×	846 1.2×	20	3.9k
Ralph Tiedt	2.4k 1.0×	2.3k 1.4×	2.8k 1.8×	737 0.9×	1.1k 1.6×	34	4.5k
Ilaria Iacobucci	2.4k 1.0×	1.1k 0.7×	1.5k 0.9×	587 0.7×	798 1.1×	165	3.7k
Taghi Manshouri	3.1k 1.3×	3.0k 1.9×	3.2k 2.0×	1.3k 1.6×	1.2k 1.7×	143	6.2k
Tetsuzo Tauchi	1.5k 0.7×	1.6k 1.0×	911 0.6×	621 0.8×	362 0.5×	146	3.1k
Thomas Kindler	1.7k 0.7×	1.5k 0.9×	768 0.5×	615 0.8×	132 0.2×	78	3.0k

Countries citing papers authored by Christopher A. Eide

Since Specialization

Citations

This map shows the geographic impact of Christopher A. Eide's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher A. Eide with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher A. Eide more than expected).

Fields of papers citing papers by Christopher A. Eide

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher A. Eide. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher A. Eide. The network helps show where Christopher A. Eide may publish in the future.

Co-authorship network of co-authors of Christopher A. Eide

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher A. Eide. A scholar is included among the top collaborators of Christopher A. Eide based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher A. Eide. Christopher A. Eide is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eide, Christopher A., Stephen E. Kurtz, Nicola Long, et al.. (2026). DDX41-Mutated AML: A Case Report and Perspectives. JCO Precision Oncology. 10(1). e2500992–e2500992.

Muratcioğlu, Serena, Christopher A. Eide, Wenqi Zuo, et al.. (2025). Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib. Science Signaling. 18(895). eadt5931–eadt5931.

Eide, Christopher A., Stephen E. Kurtz, Andy Kaempf, et al.. (2025). A rapid gene expression profiler predicts tumor responsiveness and patient outcome for standard-of-care therapies in acute myeloid leukemia. Blood. 146(Supplement 1). 657–657.

Eide, Christopher A., Stephen E. Kurtz, Andy Kaempf, et al.. (2023). Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy. Blood Cancer Discovery. 4(6). 452–467. 12 indexed citations

Kurtz, Stephen E., Christopher A. Eide, Andy Kaempf, et al.. (2022). Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia. Blood Advances. 6(10). 3062–3067. 6 indexed citations

Yenerall, Paul, Rahul K. Kollipara, Michael Peyton, et al.. (2021). Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. Cancer Research. 81(18). 4685–4695. 6 indexed citations

Coelho‐Silva, Juan Luiz, Renata Scopim‐Ribeiro, Priscila Santos Scheucher, et al.. (2020). NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy. 5(1). 5–5. 24 indexed citations

Eide, Christopher A., Stephen E. Kurtz, Andy Kaempf, et al.. (2020). Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. Leukemia. 34(9). 2342–2353. 16 indexed citations

Agarwal, Anupriya, William J. Bolosky, David B. Wilson, et al.. (2019). Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia. Proceedings of the National Academy of Sciences. 116(49). 24593–24599. 17 indexed citations

10.

Burslem, George M., Anna Reister Schultz, Daniel P. Bondeson, et al.. (2019). Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation. Cancer Research. 79(18). 4744–4753. 165 indexed citations

11.

Branford, Susan, Dennis Dong Hwan Kim, Jane F. Apperley, et al.. (2019). Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 33(8). 1835–1850. 84 indexed citations

12.

Zhang, Haijiao, Beth Wilmot, Daniel Bottomly, et al.. (2018). Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment. Blood. 132(Supplement 1). 175–175. 23 indexed citations

13.

Maxson, Julia E., Samuel B. Luty, Jason D. MacManiman, et al.. (2015). The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. Clinical Cancer Research. 22(3). 757–764. 37 indexed citations

14.

Drilon, Alexander, Romel Somwar, Jacob P. Wagner, et al.. (2015). A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer. Clinical Cancer Research. 22(10). 2351–2358. 128 indexed citations

15.

Maxson, Julia E., Monika A. Davare, Samuel B. Luty, et al.. (2015). Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research. 75(11). 2146–2150. 17 indexed citations

16.

Agarwal, Anupriya, Raffaella Pippa, Christopher A. Eide, et al.. (2014). Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia. Clinical Cancer Research. 20(8). 2092–2103. 103 indexed citations

17.

O’Hare, Thomas, Christopher A. Eide, Anupriya Agarwal, et al.. (2013). Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis. Cancer Research. 73(11). 3356–3370. 23 indexed citations

18.

Corbin, Amie S., Thomas O’Hare, Zhimin Gu, et al.. (2013). KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors. Cancer Research. 73(18). 5775–5786. 17 indexed citations

19.

Eide, Christopher A., Lauren T. Adrian, Jeffrey Tyner, et al.. (2011). The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile. Cancer Research. 71(9). 3189–3195. 77 indexed citations

20.

O’Hare, Thomas, Christopher A. Eide, Scott Wise, et al.. (2008). Activation switch pocket inhibitors target the T315I mutant of BCR-ABL. Cancer Research. 68. 4867–4867. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact